查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1924743

SPECT 和 PET 放射性药物市场按模式、放射性药物类型、适应症、最终用户和分销管道划分——2026 年至 2032 年全球预测

SPECT & PET Radiopharmaceuticals Market by Modality, Radiopharmaceutical Type, Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

SPECT 和 PET 放射性药物市场预计到 2025 年价值为 74.8 亿美元，到 2026 年将成长至 81.8 亿美元，复合年增长率为 10.28%，到 2032 年达到 148.5 亿美元。

关键市场统计数据
基准年 2025 74.8亿美元
预计年份：2026年 81.8亿美元
预测年份 2032 148.5亿美元
复合年增长率 (%) 10.28%

对SPECT和PET放射性药物、其临床作用以及在诊断和治疗途径中的策略意义进行简明扼要的基本概述

本执行摘要首先清楚阐述了SPECT和PET放射性药物作为现代诊断和治疗流程中不可或缺的工具。引言部分将这些药物置于分子生物学、成像物理学和临床决策的交叉领域，重点强调了它们在心臟病学、神经病学和肿瘤学领域实现精准诊断、治疗计划制定和疗效评估的作用。重点在于示踪剂化学和影像技术如何共同促进患者分层和个人化治疗方案的製定，从而影响从门诊诊断中心到三级甲等大学医院的临床工作流程。

新的科学突破、供应链创新和监管变革如何重塑医疗保健领域的 SPECT 和 PET 放射性药物格局

随着科学、监管和营运方面的变革共同加速创新和应用，SPECT和PET放射性药物的格局正在重塑。放射化学和迴旋加速器技术的进步扩大了可用同位素的选择范围，提高了诊断灵敏度，并促进了疾病特异性示踪剂的开发，从而提供可操作的生物学资讯。同时，检测器技术和影像重建软体的改进正在缩小不同成像方式在特定适应症方面的表现差距，促使人们重新思考临床演算法和投资重点。

对2025年美国关税调整对SPECT和PET放射性药物的采购、製造和全球分销的影响全面评估

美国宣布的2025年关税调整方案为放射性药物价值链带来了新的限制和策略考量。进口关税的变化不仅影响成品放射性药物，还会影响关键的上游工程投入，例如前驱化学品、发生器零件和特殊包装。这些调整迫使采购团队和製造商重新评估供应商选择、库存管理政策和服务交付成本模式，以确保业务连续性并遵守采购和报销框架。

针对细分市场的情报揭示了治疗方式、放射性药物化学、临床适应症、终端用户趋势以及分销管道对相关人员的影响。

对市场进行观点，有助于将科学见解转化为营运和商业决策。我们基于影像方式的市场分析区分了PET和SPECT。这种区分至关重要，因为影像方式的选择会影响示踪剂化学偏好、资本投资和临床路径设计。以PET为中心的流程往往侧重于迴旋加速器或发生器耦合的同位素，并且由于其半衰期短，需要更严格的排程；而SPECT流程则可以利用更广泛使用的Technetium试剂盒和成熟的分销模式。

解读区域趋势，了解美洲、欧洲、中东和非洲以及亚太地区对科技采纳、供应链韧性和政策环境的影响

区域趋势对放射性药物产业的技术应用、供应链设计和监管方式有显着影响。在美洲，大型医疗中心先进的临床应用、放射化学基础设施领域不断增长的私人投资，以及兼顾创新与病人安全的监管重点，共同塑造了该领域的生态系统。这些因素推动了在既定的学术-商业伙伴关係框架下进行复杂的PET示踪剂研发，同时也促使人们更加关注物流优化，以确保示踪剂在广阔地域范围内的及时供应。

在核子医学领域，推动放射性药物创新、策略联盟、商业性化规模化与价值链整合的公司，其竞争与合作概况

放射性药物领域的公司之间的差异体现在其示踪剂发现、同位素来源、生产规模化和分销网络等各个环节的整合能力上。一些公司专注于先进的放射化学平台和产品线多元化，从而推动新型配体快速进入临床试验；而另一些公司则专注于放射性药物和物流方面的卓越运营，透过完善的低温运输解决方案和区域分销中心，确保短寿命同位素的稳定准时交付。

为产业领导者提供切实可行的策略建议，以加速产品开发、确保供应链的韧性并优化临床路径。

产业领导者应优先采取三项相辅相成的策略行动，以增强自身竞争优势并确保放射性药物的稳定供应。首先，投资建构灵活的生产和采购架构，将本地生产能力与检验的关键前驱物和包装材料替代供应商结合。这种双管齐下的方法既能快速扩大产能以满足临床需求高峰，又能降低因单一供应商中断和关税而导致的成本波动风险。

严谨的调查方法，描述了所呈现的研究结果的资料来源、专家检验、分析架构和品质保证通讯协定。

本研究采用混合方法，整合了定性专家访谈、与关键相关人员的咨询以及对同行评审文献和监管指南的系统性回顾。研究邀请了包括临床研究人员、放射性药物管理人员、监管专家和供应链负责人在内的行业专家，检验主题研究结果并提取公开文件中不常体现的营运洞察。这种综合分析强调多方观点的三角验证，以减少偏见，并确保建议既体现科学有效性又体现商业性可行性。

最终综合分析，提炼出放射性药物领域的战略意义、持续挑战、投资和临床整合机会

最终的综合分析为放射性药物生态系统中的相关人员提出了策略性建议，并重点阐述了当前面临的挑战和可采取的行动。目前面临的挑战包括短寿命同位素供应链的脆弱性、不同地区法规环境和报销环境的差异，以及需要更有力的真实世界证据来支持早期应用中心以外的临床推广。应对这些挑战需要各方共同努力，加强能力建构、进行监管对话，并进行有针对性的临床检验，以证明其对病人有切实的益处。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. SPECT 和 PET 放射性药物市场依影像方式划分

  • PET
  • SPECT

9. SPECT 和 PET 放射性药物市场（按放射性药物类型划分）

  • 氟18
    • FDG
    • 非FDG
  • 镓-68
  • 铟111
  • 碘-123
  • Technetium-99M
    • 冷疗包
    • 即用型

10. SPECT 和 PET 放射性药物市场（依适应症划分）

  • 心臟病学
  • 神经病学
  • 肿瘤学

11. SPECT 和 PET 放射性药物市场（按最终用户划分）

  • 学术研究机构
  • 诊断中心
  • 医院

12. SPECT 和 PET 放射性药物市场按分销管道划分

  • 离线
  • 在线的

13. SPECT 和 PET 放射性药物市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

14. SPECT 和 PET 放射性药物市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国 SPECT 与 PET 放射性药物市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国SPECT与PET放射性药物市场

第十七章 中国SPECT与PET放射性药物市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Advanced Accelerator Applications
  • Bayer AG
  • Bracco Imaging SpA
  • Cardinal Health, Inc.
  • Curium Pharma
  • Eckert & Ziegler
  • GE Healthcare
  • IBA Molecular
  • Isotopia Molecular Imaging Ltd.
  • Jubilant Pharma Limited
  • Lantheus Holdings, Inc.
  • Life Molecular Imaging GmbH
  • Mallinckrodt plc
  • Nihon Medi-Physics Co., Ltd.
  • NorthStar Medical Radioisotopes, LLC
  • Novartis AG
  • Positron Corporation
  • Spectrum Pharmaceuticals, Inc.
  • Telix Pharmaceuticals Limited
Product Code: MRR-7A380DA7C46E

The SPECT & PET Radiopharmaceuticals Market was valued at USD 7.48 billion in 2025 and is projected to grow to USD 8.18 billion in 2026, with a CAGR of 10.28%, reaching USD 14.85 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.48 billion
Estimated Year [2026] USD 8.18 billion
Forecast Year [2032] USD 14.85 billion
CAGR (%) 10.28%

A concise foundational overview introducing SPECT and PET radiopharmaceuticals, their clinical roles, and strategic relevance to diagnostic and therapeutic pathways

This executive summary opens with a clear framing of SPECT and PET radiopharmaceuticals as indispensable tools within contemporary diagnostic and therapeutic pathways. The introduction situates these agents at the intersection of molecular biology, imaging physics, and clinical decision-making, highlighting their role in enabling precision diagnostics, treatment planning, and response assessment across cardiology, neurology, and oncology. It emphasizes how tracer chemistry and imaging modality together inform patient stratification and personalized care pathways, shaping clinical workflows from outpatient diagnostic centers to tertiary academic hospitals.

The section underscores the technological differentiation between PET and SPECT modalities and how radiochemistry choices influence diagnostic specificity, tracer availability, and operational workflows. It also outlines key stakeholders and value chain touchpoints, from isotope producers and radiopharmacies to imaging centers and regulatory authorities, while noting the operational dependencies that influence access and uptake. Finally, the introduction establishes the analytical perspective of this report: to synthesize scientific advancements, regulatory trends, supply chain considerations, and commercial strategies that will inform executive decision-making in the near term.

How emerging scientific breakthroughs, supply chain innovations, and regulatory evolution are reshaping the SPECT and PET radiopharmaceutical landscape across care settings

The landscape of SPECT and PET radiopharmaceuticals is being reshaped by a convergence of scientific, regulatory, and operational changes that collectively accelerate innovation and adoption. Advances in radiochemistry and cyclotron capabilities have broadened the palette of usable isotopes, enabling more disease-specific tracers that improve diagnostic sensitivity and provide actionable biological insights. Concurrently, improvements in detector technology and image reconstruction software have narrowed the performance gap between modalities in certain indications, prompting reassessment of clinical algorithms and investment priorities.

On the regulatory front, there is a discernible trend toward adaptive review pathways and greater regulatory dialogue around centralized versus decentralized production models. These developments are encouraging manufacturers and healthcare providers to experiment with new supply arrangements, including regional radiopharmacies and on-site synthesis, while simultaneously raising expectations for robust quality assurance and cold-chain management. In parallel, strategic collaborations among industry, academic centers, and contract development organizations are accelerating translational research and commercial-scale validation of next-generation tracers. Taken together, these shifts are creating a more dynamic environment in which innovation, supply resilience, and outcome-driven evidence increasingly determine commercial success.

Comprehensive assessment of how United States tariff adjustments implemented in 2025 affect sourcing, manufacturing, and global distribution of SPECT and PET radiopharmaceuticals

Tariff adjustments announced for the United States in 2025 have introduced new constraints and strategic considerations across the radiopharmaceutical value chain. Changes in import duties affect not only finished radiopharmaceutical products but also critical upstream inputs such as precursor chemicals, generator components, and specialized packaging materials. These adjustments have prompted procurement teams and manufacturers to reevaluate supplier selection, inventory policies, and cost-to-serve models to preserve operational continuity and maintain compliance with procurement and reimbursement frameworks.

In response, companies are increasingly exploring regionalization strategies that reduce exposure to cross-border tariff volatility. Such strategies include diversifying sourcing to alternative jurisdictions, increasing local or regional production capacity, and negotiating longer-term supplier agreements to stabilize input costs. These operational shifts have downstream implications for distribution timelines and inventory management, necessitating closer coordination among radiopharmacies, logistics providers, and imaging centers to ensure tracer availability aligns with clinical scheduling.

Regulatory and contract terms are also under scrutiny; procurement teams are updating contractual clauses to better allocate tariff-related risk and to secure price adjustments or supply guarantees. Meanwhile, health systems and providers are assessing whether changes in sourcing influence clinical operations or patient access, and they are engaging suppliers to develop contingency playbooks. Overall, the tariff-driven adjustments in 2025 have reinforced the strategic importance of supply chain flexibility, contractual clarity, and proactive stakeholder communication in preserving access to critical diagnostic agents.

Segment-focused intelligence revealing modality, radiopharmaceutical chemistries, clinical indications, end-user dynamics, and distribution channel implications for stakeholders

The sector's segmentation provides a pragmatic lens to translate scientific capability into operational and commercial choices. Based on Modality, the market is studied across PET and SPECT, a distinction that remains central because modality selection drives tracer chemistry preferences, equipment investments, and clinical pathway design. PET-centered workflows emphasize cyclotron or generator-linked isotopes and often demand tighter scheduling due to shorter half-lives, whereas SPECT workflows can leverage more widely available technetium-based kits and established distribution patterns.

Based on Radiopharmaceutical Type, the market is studied across Fluorine 18, Gallium 68, Indium 111, Iodine 123, and Technetium 99M. Within this framework, Fluorine 18 is further studied across FDG and Non FDG conjugates, reflecting the dual role of FDG as a longstanding oncology workhorse and the growing diversity of non-FDG tracers targeting specific molecular pathways. Technetium 99M is further studied across Cold Kits and Ready To Use formulations, recognizing that kit-based approaches support decentralized preparation while ready-to-use formats facilitate streamlined operations in high-throughput centers.

Based on Indication, the market is studied across Cardiology, Neurology, and Oncology, acknowledging that clinical utility, reimbursement pathways, and evidence requirements vary substantially by therapeutic area. Based on End User, the market is studied across Academic And Research Institutes, Diagnostic Centers, and Hospitals, which captures the operational and procurement heterogeneity between research-grade production environments and routine clinical service providers. Based on Distribution Channel, the market is studied across Direct Tender, Online Channels, and Third Party Logistics, reflecting how procurement and logistics choices influence availability, lead times, and compliance obligations. An integrated view across these segmentations clarifies where investment in tracer development, production capacity, or distribution infrastructure will yield the greatest clinical and commercial returns.

Regional dynamics decoded to understand Americas, Europe Middle East and Africa, and Asia-Pacific influences on technology adoption, supply resilience, and policy environments

Regional dynamics materially influence technology adoption, supply chain design, and regulatory approaches across the radiopharmaceutical landscape. In the Americas, ecosystems are characterized by a mix of advanced clinical adoption in major healthcare centers, growing private investment in radiochemistry infrastructure, and an evolving regulatory emphasis on balancing innovation with patient safety. These factors encourage development of complex PET tracers within established academic and commercial partnerships, while also prompting attention to logistical optimization for timely tracer delivery across large geographic spans.

Europe, Middle East & Africa present a heterogeneous landscape in which regulatory harmonization across blocks and national differences in reimbursement create both opportunities and friction points. Western European markets have mature adoption curves for novel tracers and supportive reimbursement mechanisms for evidence-backed indications, whereas other markets in the region are more price-sensitive and prioritize supply reliability. Middle Eastern centers of excellence are rapidly adopting advanced tracers, often through strategic partnerships, while African markets are beginning to address foundational infrastructure and workforce capacity to enable broader access.

Asia-Pacific is characterized by rapid capacity expansion, significant investments in cyclotron capabilities, and a strong appetite for innovative imaging agents that support oncology and neurology care pathways. Several markets in the region are building domestic radiopharmaceutical manufacturing capabilities to reduce dependency on imports, which in turn accelerates regional clinical trials and commercial rollouts. Across all regions, cross-border supply chain resilience, regulatory clarity, and local clinical evidence generation remain decisive factors shaping adoption trajectories.

Competitive and collaborative profiles of companies shaping radiopharmaceutical innovation, strategic partnerships, commercial scale-up, and value chain integration in nuclear medicine

Companies operating in the radiopharmaceutical segment are differentiated by their integrated capabilities across tracer discovery, isotope procurement, manufacturing scale-up, and distribution networks. Some organizations concentrate on advanced radiochemistry platforms and pipeline diversification, enabling rapid translation of novel ligands into clinical trials. Others focus on operational excellence in radiopharmacy and logistics, ensuring consistent on-time delivery of short-lived isotopes through robust cold-chain solutions and regional distribution hubs.

Strategic partnerships between technology developers, academic centers, and contract manufacturing organizations have become a common vehicle to bridge early-stage innovation and commercial supply. These collaborations mitigate development risk, leverage specialized manufacturing expertise, and expand access to specialized facilities necessary for regulatory submissions and clinical validation. At the same time, mergers, acquisitions, and licensing agreements are increasingly used to secure proprietary tracers or to consolidate supply chains, creating vertically integrated capabilities that can reduce time-to-market for selected indications.

Across the competitive landscape, differentiation is emerging through investments in tracer specificity, manufacturing agility, and evidence generation. Companies that align tracer development with clear clinical utility, scalable production pathways, and well-articulated pricing and reimbursement strategies are best positioned to translate scientific promise into clinical impact and commercial sustainability.

Actionable strategic recommendations for industry leaders to accelerate product development, secure resilient supply chains, and optimize clinical adoption pathways

Industry leaders should prioritize three complementary strategic actions to strengthen competitive positioning and ensure resilient access to radiopharmaceuticals. First, invest in flexible manufacturing and sourcing architectures that combine regional production capacity with validated alternative suppliers for critical precursors and packaging materials. This dual approach reduces exposure to single-source disruptions and tariff-driven cost volatility while enabling rapid scaling to meet clinical demand peaks.

Second, accelerate clinically focused evidence generation by aligning tracer development programs with clear clinical endpoints and real-world utility studies that demonstrate impact on diagnostic confidence, treatment selection, or patient outcomes. Embedding health economics analyses and payer engagement early in development will smooth adoption pathways and support reimbursement discussions. Third, foster strategic commercial partnerships that integrate manufacturing, distribution, and clinical adoption initiatives; these collaborations should include clear contractual provisions for risk-sharing around supply disruptions, quality compliance, and intellectual property management.

Additionally, leaders should invest in workforce development and digital infrastructure to optimize scheduling, inventory management, and regulatory documentation. By combining operational resilience with targeted clinical evidence and collaborative commercialization, organizations can accelerate adoption while managing cost and compliance pressures.

Rigorous research methodology explaining data sources, expert validation, analytical frameworks, and quality assurance protocols underpinning the insights presented

This research draws upon a mixed-methods approach that integrates qualitative expert interviews, primary stakeholder consultations, and a systematic review of peer-reviewed literature and regulatory guidance. Industry subject-matter experts, including clinical investigators, radiopharmacy managers, regulatory specialists, and supply chain leaders, were engaged to validate thematic findings and to surface operational realities that are not always visible in public documentation. The synthesis emphasizes triangulating perspectives to reduce bias and to ensure that recommendations reflect both scientific plausibility and commercial practicality.

Analytical frameworks applied in the study include value chain mapping, regulatory pathway comparison, and scenario analysis for supply chain resilience. Data quality assurance protocols encompassed source verification, cross-referencing of regulatory statements, and iterative validation with domain experts. Where appropriate, comparative case studies were used to illustrate how different production models and distribution strategies perform under varying operational and policy constraints. Throughout, emphasis was placed on transparency in assumptions, clear documentation of data sources, and rigorous peer review of analytical outputs to bolster confidence in the insights provided.

Concluding synthesis that distills strategic implications, persistent challenges, and opportunities for investment and clinical integration within the radiopharmaceutical sector

The closing synthesis distills the strategic implications for stakeholders across the radiopharmaceutical ecosystem, underscoring persistent challenges and actionable opportunities. Persistent challenges include supply chain fragility for short-lived isotopes, variability in regulatory and reimbursement environments across regions, and the need for stronger real-world evidence to support clinical adoption beyond early-adopter centers. Addressing these challenges will require concerted efforts in capacity building, regulatory dialogue, and targeted clinical validation that demonstrates meaningful patient benefit.

Opportunities exist in expanding tracer specificity for underserved indications, optimizing distribution models to balance centralization and decentralization, and leveraging digital tools to improve scheduling and resource allocation. Strategic investments in regional manufacturing capacity and evidence-generation partnerships can unlock broader clinical use while reducing exposure to geopolitical and tariff pressures. Ultimately, stakeholders that blend scientific rigor with operational adaptability and proactive payer engagement will be best positioned to translate radiopharmaceutical innovation into sustainable clinical impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. SPECT & PET Radiopharmaceuticals Market, by Modality

  • 8.1. PET
  • 8.2. SPECT

9. SPECT & PET Radiopharmaceuticals Market, by Radiopharmaceutical Type

  • 9.1. Fluorine 18
    • 9.1.1. FDG
    • 9.1.2. Non FDG
  • 9.2. Gallium 68
  • 9.3. Indium 111
  • 9.4. Iodine 123
  • 9.5. Technetium 99M
    • 9.5.1. Cold Kits
    • 9.5.2. Ready To Use

10. SPECT & PET Radiopharmaceuticals Market, by Indication

  • 10.1. Cardiology
  • 10.2. Neurology
  • 10.3. Oncology

11. SPECT & PET Radiopharmaceuticals Market, by End User

  • 11.1. Academic And Research Institutes
  • 11.2. Diagnostic Centers
  • 11.3. Hospitals

12. SPECT & PET Radiopharmaceuticals Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. SPECT & PET Radiopharmaceuticals Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. SPECT & PET Radiopharmaceuticals Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. SPECT & PET Radiopharmaceuticals Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States SPECT & PET Radiopharmaceuticals Market

17. China SPECT & PET Radiopharmaceuticals Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Advanced Accelerator Applications
  • 18.6. Bayer AG
  • 18.7. Bracco Imaging S.p.A.
  • 18.8. Cardinal Health, Inc.
  • 18.9. Curium Pharma
  • 18.10. Eckert & Ziegler
  • 18.11. GE Healthcare
  • 18.12. IBA Molecular
  • 18.13. Isotopia Molecular Imaging Ltd.
  • 18.14. Jubilant Pharma Limited
  • 18.15. Lantheus Holdings, Inc.
  • 18.16. Life Molecular Imaging GmbH
  • 18.17. Mallinckrodt plc
  • 18.18. Nihon Medi-Physics Co., Ltd.
  • 18.19. NorthStar Medical Radioisotopes, LLC
  • 18.20. Novartis AG
  • 18.21. Positron Corporation
  • 18.22. Spectrum Pharmaceuticals, Inc.
  • 18.23. Telix Pharmaceuticals Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FDG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FDG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FDG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY NON FDG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY NON FDG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY NON FDG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY GALLIUM 68, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY GALLIUM 68, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY GALLIUM 68, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDIUM 111, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDIUM 111, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDIUM 111, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY IODINE 123, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY IODINE 123, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY IODINE 123, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY COLD KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY COLD KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY COLD KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY READY TO USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY READY TO USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY READY TO USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. GCC SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 142. GCC SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. GCC SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, 2018-2032 (USD MILLION)
  • TABLE 144. GCC SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, 2018-2032 (USD MILLION)
  • TABLE 145. GCC SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 146. GCC SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. GCC SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. G7 SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. G7 SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 166. G7 SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. G7 SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, 2018-2032 (USD MILLION)
  • TABLE 168. G7 SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, 2018-2032 (USD MILLION)
  • TABLE 169. G7 SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 170. G7 SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. G7 SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. NATO SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 174. NATO SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. NATO SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, 2018-2032 (USD MILLION)
  • TABLE 176. NATO SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, 2018-2032 (USD MILLION)
  • TABLE 177. NATO SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 178. NATO SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. NATO SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOPHARMACEUTICAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE 18, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM 99M, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA SPECT & PET RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)